# Antibodies to myelin oligodendrocyte glycoprotein in optic perineuritis

**Authors:** Shanshan Cao, Yuan Zhang, Xintong Xu, Mingming Sun, Chunyan Pan, Yuhang Wang, Shihui Wei, Quangang Xu, Huanfen Zhou

PMC · DOI: 10.3389/fimmu.2025.1657600 · Frontiers in Immunology · 2025-10-29

## TL;DR

This study finds that antibodies to myelin oligodendrocyte glycoprotein are linked to specific clinical features in optic perineuritis, aiding diagnosis and prognosis.

## Contribution

The study identifies distinct clinical characteristics of MOG-IgG-positive optic perineuritis, offering insights for diagnosis and treatment.

## Key findings

- MOG-IgG-positive patients were younger and had higher relapse rates compared to seronegative cases.
- MOG-IgG-positive patients showed better visual recovery after the first episode and at final follow-up.
- Detection of MOG-IgG in optic perineuritis may improve diagnosis and guide treatment strategies.

## Abstract

This study aimed to investigate the prevalence of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in patients with optic perineuritis (OPN) and to analyze the clinical characteristics and prognosis of MOG-IgG–seropositive cases.

A retrospective review was conducted of OPN patients diagnosed at the Neuro-ophthalmology Department of the Chinese People’s Liberation Army (PLA) General Hospital between January 2020 and February 2023. Patients were classified into MOG-IgG–positive and seronegative groups based on cell-based assay (CBA) results. Demographic data, clinical manifestations, and visual outcomes were compared between the two groups.

A total of 33 patients (44 eyes) were included, with a mean onset age of 32.7 years (range 6–79) and a male-to-female ratio of 1:2. Bilateral involvement was observed in 33.3% of cases. Eye pain and optic disc swelling were present in 72.7% and 75.8% of patients, respectively. MOG-IgG was detected in 8 patients (24.2%). Compared with seronegative OPN, MOG-IgG-positive patients were significantly younger (mean age 20.8 years vs. 36.6 years, P = 0.034) and had a higher annual relapse rate (median 1.19 vs. 0.31, P = 0.008). All MOG-IgG-positive patients achieved visual acuity (VA) ≥20/40 after the first episode (100.0% vs. 45.5% in seronegative cases, P = 0.005), with this difference persisting at final follow-up (78.6% vs. 47.4%, P = 0.044).

These findings highlight distinct clinical characteristics of MOG-IgG-positive OPN, including younger age, higher relapse rates, and superior visual recovery. Detection of MOG-IgG in OPN may facilitate early diagnosis, prognosis prediction, and guide individualized therapeutic strategies.

## Linked entities

- **Diseases:** optic perineuritis (MONDO:0044690)

## Full-text entities

- **Genes:** MOG (myelin oligodendrocyte glycoprotein) [NCBI Gene 4340] {aka BTN6, BTNL11, MOGIG2, NRCLP7}
- **Diseases:** optic disc swelling (MESH:D010211), Eye pain (MESH:D058447), OPN (MESH:D052958)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12605376/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12605376/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12605376/full.md

---
Source: https://tomesphere.com/paper/PMC12605376